TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00074607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Schedule~Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).~In the absence of disease progression or DLT, patients may proceed to consolidation.~Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.~Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year.
Study: NCT03196518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Imaging
Description: PET/CT study immediately after injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-tetrafluoroborate (18F-TFB)
Description: administration of a single dose of approximately 5-10 mCi 18F-TFB (mass \<= 50 μg) for imaging purposes
Study: NCT02077374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Description: 25 mg BID for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo BID for 28 Days
Study: NCT02875704

Intervention type: OTHER
Intervention: Anterior Chamber (AC) Tap
Description: Aqueous Samples will be collected for measurement of biomarkers

Intervention type: OTHER
Intervention: Anterior Chamber (AC) Tap
Description: Aqueous Samples will be collected for measurement of biomarkers
Study: NCT00470418

Intervention type: DRUG
Group type: OTHER
Intervention: NIC5-15
Description: a natural product, found in many foods and plants with mild insulin sensitizing effects
Study: NCT00713336

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZD4054 Placebo
Description: 3 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: 1 capsule
Study: NCT00470418

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study: NCT02832336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vivarin
Description: Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fiber
Description: Fiber will be used as placebo.
Study: NCT01463202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot medroxyprogesterone acetate
Description: Postpartum administration of DMPA (prior to hospital discharge)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot medroxyprogesterone acetate
Description: Delayed administration of DMPA (4-6 weeks postpartum)
Study: NCT02825212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harvoni
Description: 12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
Study: NCT00713336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: 1 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo
Description: 1 capsule
Study: NCT02825212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: once daily for 12 weeks (naïve subjects, non-cirrhotic treatment experienced or treatment experienced subjects with compensated cirrhosis) for genotype 1-6 subjects.
Study: NCT04003987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 20ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 20ml
Study: NCT00713336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 Placebo
Description: 2 tablets
Study: NCT04003987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, 0.125%
Description: 60ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine, 0.125%
Description: 60ml
Study: NCT02122367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)
Description: HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
Study: NCT00953940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic saline
Description: Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
Study: NCT02581969

Intervention type: DRUG
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Administered 20-30 IU/kg 3 times a week
Study: NCT00713336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 30mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10mg tablet
Study: NCT00355862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)
Description: center specific therapeutic regimen without mTOR inhibition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus based immunosuppression
Study: NCT01416727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emergency Psychiatry Immersion Course
Description: A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observed SKills in the Emergency Room
Description: For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
Study: NCT03379649

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
Study: NCT02581969

Intervention type: DRUG
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Administered only for bleeding episodes
Study: NCT03379649

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
Study: NCT04327219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CDED diet
Description: examine the microbial, mucosal and immunological changes of the pouch during one year post IPAA, and examine the impact of the CDED on disease activity and dysbiosis in adults suffering from active pouchitis.
Study: NCT03341195

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS messages and automated calls
Description: The intervention consists of SMS and automated calls based messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS messages and automated calls
Description: The intervention consists of SMS and automated calls based messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS messages and automated calls
Description: The intervention consists of SMS and automated calls based messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS messages and automated calls
Description: The intervention consists of SMS and automated calls based messages
Study: NCT02517996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
Study: NCT04248933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Delivered Behavioral Activation (Peer Activate)
Description: The Peer Activate intervention consisted of weekly one-hour BA sessions led by a peer recovery specialist (PRS) for up to 12 weekly sessions, with the first five being the core treatment sessions and content, and the subsequent seven designed to reinforce core content. In these sessions, participants received individualized support in learning skills to assist in their retention and persistence in methadone treatment and were guided through exercises aimed at incorporating substance-free, rewarding activities into their daily life.
Study: NCT03937414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The OSNA assay
Description: SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.
Study: NCT00719888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT04128163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1206
Description: subcutaneous injection of 60 mg（60mg:1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: subcutaneous injection of（1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU
Study: NCT00492310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: vinyasa yoga

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive therapy
Description: cognitive behavioral therapy once weekly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive therapy
Description: cognitive behavioral therapy once weekly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: vinyasa yoga twice weekly with smoking cessation once weekly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: wellness
Description: wellness program with smoking cessation
Study: NCT04026607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
Study: NCT00445965

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT00719888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV and PO
Study: NCT03052998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Effect of Ivermectin on frequency of seizures
Study: NCT00316121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEALOS and Leopard Cage
Description: Placement in interbody space

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leopard Cage and Autograft
Description: Placement in the interbody space
Study: NCT02676726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraperitoneal Laparoscopic aortic lymphadenectomy
Description: Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperitoneal Laparoscopic aortic lymphadenectomy
Description: Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
Study: NCT04464499

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG measurement
Description: Simultaneous recording of a single-lead ECG signal with the Withings BPM Core and ECG signal for the reference 12-lead ECG

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG measurement
Description: Simultaneous recording of a single-lead ECG signal with the Withings BPM Core and ECG signal for the reference 12-lead ECG
Study: NCT02770274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Dual therapy with Cilostazol 100 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Monotherapy with aspirin 100 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Monotherapy with aspirin 100 mg once daily
Study: NCT02428595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse™ System
Description: The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System.
Study: NCT02486107

Intervention type: PROCEDURE
Intervention: surgical procedure

Intervention type: PROCEDURE
Intervention: surgical procedure
Study: NCT00719888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV and PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double-Unit Umbilical Cord Blood Transplantation
Description: Undergo double-unit UCBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double-Unit Umbilical Cord Blood Transplantation
Description: Undergo double-unit UCBT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV and PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo high-dose or moderate-intensity TBI
Study: NCT02486107

Intervention type: PROCEDURE
Intervention: surgical procedure
Study: NCT00898313

Intervention type: GENETIC
Intervention: comparative genomic hybridization
Description: Collection of sputum, blood, urine, and a small amount of lung tissue.

Intervention type: GENETIC
Intervention: gene expression microarray analysis
Description: Collection of sputum, blood, urine, and a small amount of lung tissue.

Intervention type: GENETIC
Intervention: proteomic profiling analysis
Description: Collection of sputum, blood, urine, and a small amount of lung tissue.

Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: Collection of sputum, blood, urine, and a small amount of lung tissue.

Intervention type: PROCEDURE
Intervention: nasal brushing
Description: Using a brush, superficial cells are removed from the nose.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Venous blood will be collected

Intervention type: PROCEDURE
Intervention: Urine collection
Description: Subjects will be asked to provide a urine specimen.
Study: NCT00719888

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo high-dose or moderate-intensity TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo UCBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo UCBT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study: NCT02681315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HHHFNC 6 liter minute
Description: Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHHFNC 3 liters/min
Description: Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
Study: NCT02353390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Water Hydration
Description: Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
Study: NCT02479139

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle for ANT-1207 liniment formulation without active ingredient.
Study: NCT00898313

Intervention type: PROCEDURE
Intervention: sputum sample
Description: Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.

Intervention type: PROCEDURE
Intervention: fluorescence bronchoscopy with airway biopsy
Description: A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
Study: NCT02479139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: Botulinum toxin Type A topical liniment (ANT-1207).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: Botulinum toxin Type A topical liniment (ANT-1207).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: Botulinum toxin Type A topical liniment (ANT-1207).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: Botulinum toxin Type A topical liniment (ANT-1207).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1207
Description: Botulinum toxin Type A topical liniment (ANT-1207).
Study: NCT01727336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalantercept and axitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalantercept and axitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalantercept and axitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalantercept and axitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalantercept and axitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and axitinib
Study: NCT03870425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distribution pattern of dietary proteins (minced meat)
Description: Study effect of an even or skewed distribution pattern of dietary protein

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distribution pattern of dietary proteins (minced meat)
Description: Study effect of an even or skewed distribution pattern of dietary protein
Study: NCT03645512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corporate Athlete Resilience (CAR) Training Program
Description: A 1-day training program developed by the J\&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.